Literature DB >> 18755556

Predictors of acute esophagitis in lung cancer patients treated with concurrent three-dimensional conformal radiotherapy and chemotherapy.

Núria Rodríguez1, Manuel Algara, Palmira Foro, Marti Lacruz, Anna Reig, Ismael Membrive, Joan Lozano, José Luis López, Jaime Quera, Enric Fernández-Velilla, Xavier Sanz.   

Abstract

PURPOSE: To evaluate the risk factors for acute esophagitis (AET) in lung cancer patients treated with concurrent 3D-CRT and chemotherapy. METHODS AND MATERIALS: Data from 100 patients treated with concurrent chemoradiotherapy with a mean dose of 62.05 +/- 4.64 Gy were prospectively evaluated. Esophageal toxicity was graded according to criteria of the Radiation Therapy Oncology Group. The following dosimetric parameters were analyzed: length and volume of esophagus in treatment field, percentage of esophagus volume treated to >or=10, >or=20, >or=30, >or=35, >or=40, >or=45, >or=50, >or=55, and >or=60 Gy, and the maximum (D(max)) and mean doses (D(mean)) delivered to the esophagus. Also, we developed an esophagitis index (EI) to account the esophagitis grades over treatment time.
RESULTS: A total of 59 patients developed AET (Grade 1, 26 patients; Grade 2, 29 patients; and Grade 3, 4 patients). V50 was associated with AET duration (p = 0.017), AET Grade 1 duration (p = 0.016), maximum analgesia (p = 0.019), esophagitis index score (p = 0.024), and AET Grade >or=1 (p = 0.058). If V50 is <30% there is a 47.3% risk of AET Grade >or=1, which increases to 73.3% if V50 is >or=30% (p = 0.008). The predictive abilities of models (sensitivity and specificity) were calculated by receiver operating characeristic curves.
CONCLUSIONS: According to the receiver operating characeristic curve analysis, the 30% of esophageal volume receiving >or=50 Gy was the most statistically significant factor associated with AET Grade >or=1 and maximum analgesia (A(max)). There was an association with AET Grade >or=2 but it did not achieve statistical significance (p = 0.076).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18755556     DOI: 10.1016/j.ijrobp.2008.04.064

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  11 in total

1.  Spanish radiobiological pattern of care in lung cancer: a GOECP/SEOR study.

Authors:  J A González; M Chust; R Delgado; A Gómez; N Rodríguez; M J Ruiz; F Casas
Journal:  Clin Transl Oncol       Date:  2010-04       Impact factor: 3.405

Review 2.  Radiation dose-volume effects in the esophagus.

Authors:  Maria Werner-Wasik; Ellen Yorke; Joseph Deasy; Jiho Nam; Lawrence B Marks
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 3.  Esophagitis, treatment-related toxicity in non-small cell lung cancer.

Authors:  Voichita Bar-Ad; Nitin Ohri; Maria Werner-Wasik
Journal:  Rev Recent Clin Trials       Date:  2012-02

4.  Accelerated hypofractionated radiation therapy (AHRT) for non-small-cell lung cancer: can we leave standard fractionation?

Authors:  N Rodríguez de Dios; X Sanz; P Foro; I Membrive; A Reig; A Ortiz; R Jiménez; M Algara
Journal:  Clin Transl Oncol       Date:  2016-08-23       Impact factor: 3.405

Review 5.  Gastrointestinal toxicity associated to radiation therapy.

Authors:  Mario López Rodríguez; Margarita Martín Martín; Laura Cerezo Padellano; Alicia Marín Palomo; Yamile Ibáñez Puebla
Journal:  Clin Transl Oncol       Date:  2010-08       Impact factor: 3.405

6.  Imaging Study of Pseudo-CT Synthesized From Cone-Beam CT Based on 3D CycleGAN in Radiotherapy.

Authors:  Hongfei Sun; Rongbo Fan; Chunying Li; Zhengda Lu; Kai Xie; Xinye Ni; Jianhua Yang
Journal:  Front Oncol       Date:  2021-03-12       Impact factor: 6.244

7.  Normal tissue complication models for clinically relevant acute esophagitis (≥ grade 2) in patients treated with dose differentiated accelerated radiotherapy (DART-bid).

Authors:  Franz Zehentmayr; Matthias Söhn; Ann-Katrin Exeli; Karl Wurstbauer; Almut Tröller; Heinz Deutschmann; Gerd Fastner; Christoph Fussl; Philipp Steininger; Manfred Kranzinger; Claus Belka; Michael Studnicka; Felix Sedlmayer
Journal:  Radiat Oncol       Date:  2015-05-28       Impact factor: 3.481

Review 8.  Advances in dosimetry and biological predictors of radiation-induced esophagitis.

Authors:  Yang Yu; Hui Guan; Yuanli Dong; Ligang Xing; Xiaolin Li
Journal:  Onco Targets Ther       Date:  2016-01-28       Impact factor: 4.147

9.  A model combining age, equivalent uniform dose and IL-8 may predict radiation esophagitis in patients with non-small cell lung cancer.

Authors:  Shulian Wang; Jeff Campbell; Matthew H Stenmark; Paul Stanton; Jing Zhao; Martha M Matuszak; Randall K Ten Haken; Feng-Ming Kong
Journal:  Radiother Oncol       Date:  2018-03       Impact factor: 6.280

10.  Risk factors of radiation-induced acute esophagitis in non-small cell lung cancer patients treated with concomitant chemoradiotherapy.

Authors:  ZiCheng Zhang; Jin Xu; Tao Zhou; Yan Yi; HongSheng Li; HongFu Sun; Wei Huang; DongQing Wang; BaoSheng Li; GuoGuang Ying
Journal:  Radiat Oncol       Date:  2014-02-15       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.